Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
D. Ross Camidge(University of Colorado Denver), Shun Lü(Shanghai Jiao Tong University), Е. А. Филиппова, Nathalie Daaboul(Hôpital Charles-Le Moyne), Ji‐Youn Han(National Cancer Centre Japan), Chunling Liu(Xinjiang Medical University), Jim Looman(AbbVie (United States)), David Planchard(Université Paris-Saclay), Chih‐Hsi S. Kuo(Chang Gung University), Fedor Moiseenko, Kazumi Nishino(Osaka Medical Center for Cancer and Cardiovascular Diseases), Peter Ansell(AbbVie (United States)), Jonathan W. Goldman(University of California, Los Angeles), Christina S. Baik(Seattle Cancer Care Alliance), Pascale Tomasini(Centre National de la Recherche Scientifique), İrfan Çiçin(Istinye University), Alona Zer(Rambam Health Care Campus), Se‐Hoon Lee(Samsung Medical Center), Shang‐Yin Wu(National Cheng Kung University Hospital), Hidehito Horinouchi(Tokyo National Hospital), Aaron S. Mansfield(Mayo Clinic), Kristof Cuppens(Jessa Hospital), Nuran Katgı(Sağlık Bilimleri Üniversitesi), Martha Li(AbbVie (United States)), Nicolas Girard(Institut Curie), Shobhit Baijal(University Hospitals Birmingham NHS Foundation Trust), Summer Xia(AbbVie (United States)), Ellen Bolotin(AbbVie (United States)), Penelope A. Bradbury(University Health Network), Christine K. Ratajczak(AbbVie (United States)), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Mor Moskovitz(Rambam Health Care Campus), Jair Bar(Tel Aviv University)
Cited by 131
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k